- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2017
- Public Summary Document (PSD) November 2017 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2017 PBAC Meeting - Word
Atezolizumab – November 2017
Atezolizumab: Solution concentrate for I.V. infusion 1200 mg in 20 mL; Tecentriq®
Last updated
2 March 2018